Entresto(sacubitril valsartan)使用说明书2015第二版.pdf

HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS AND STRENGTHS These highlights do not include all the information needed to use ENTRESTO safely and effectively. See full prescribing information for  Film-coated tablets (sacubitril/valsartan): 24/26 mg; 49/51 mg; 97/103 mg ENTRESTO. (3) ENTRESTO™ (sacubitril and valsartan) tablets, for oral use CONTRAINDICATIONS Initial U.S. Approval: 2015  Hypersensitivity to any component. (4)  History of angioedema related to previous ACE inhibitor or ARB therapy. WARNING: FETAL TOXICITY (4) See full prescribing information for complete boxed warning .  Concomitant use with ACE inhibitors. (4, 7.1)  When pregnancy is detected, discontinue ENTRESTO as soon as  Concomitant use with aliskiren in patients with diabetes. (4, 7.1) possible. (5.1)  Drugs that act directly on the renin-angiotensin system can cause WARNINGS AND PRECAUTIONS injury and death to the developing fetus. (5.1)  Observe for signs and symptoms of angioedema and hypotension. (5.2, 5.3)  Monitor renal function and potassium in suscep